Lilly/Amylin’s Byetta Type 2 Diabetes Therapy To Launch June 1
This article was originally published in The Pink Sheet Daily
Executive Summary
Amylin will put 325 reps behind exenatide, in addition to a Lilly sales force. The firms will target 60,000 physicians in first six months. First-in-class gut hormone follows approval of Amylin’s diabetes therapy Symlin in March.
You may also be interested in...
Lilly Will Add 40% Capacity To Diabetes Sales Force In Q1
Firm also announces the submission of an sNDA for Evista for breast cancer risk reduction.
Lilly Will Add 40% Capacity To Diabetes Sales Force In Q1
Firm also announces the submission of an sNDA for Evista for breast cancer risk reduction.
Lilly/Amylin Look To Limit Byetta Access Due To Cartridge Shortage
Exenatide supplies for patients already on the therapy will be maintained, Lilly said.